DE593491T1 - LHRH-Antagonisten. - Google Patents
LHRH-Antagonisten.Info
- Publication number
- DE593491T1 DE593491T1 DE0593491T DE92906562T DE593491T1 DE 593491 T1 DE593491 T1 DE 593491T1 DE 0593491 T DE0593491 T DE 0593491T DE 92906562 T DE92906562 T DE 92906562T DE 593491 T1 DE593491 T1 DE 593491T1
- Authority
- DE
- Germany
- Prior art keywords
- sequence position
- residue
- pharmaceutically acceptable
- peptide according
- alanine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229940124041 Luteinizing hormone releasing hormone (LHRH) antagonist Drugs 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract 14
- 239000002474 gonadorelin antagonist Substances 0.000 claims abstract 4
- 239000003098 androgen Substances 0.000 claims abstract 2
- 229940011871 estrogen Drugs 0.000 claims abstract 2
- 239000000262 estrogen Substances 0.000 claims abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract 2
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 claims 5
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 239000000825 pharmaceutical preparation Substances 0.000 claims 3
- NIGWMJHCCYYCSF-MRVPVSSYSA-N (2r)-2-amino-3-(4-chlorophenyl)propanoic acid Chemical compound OC(=O)[C@H](N)CC1=CC=C(Cl)C=C1 NIGWMJHCCYYCSF-MRVPVSSYSA-N 0.000 claims 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical class CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N phenylalanine group Chemical group N[C@@H](CC1=CC=CC=C1)C(=O)O COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims 2
- HQMLIDZJXVVKCW-UWTATZPHSA-N (2r)-2-aminopropanamide Chemical compound C[C@@H](N)C(N)=O HQMLIDZJXVVKCW-UWTATZPHSA-N 0.000 claims 1
- 229940122344 Peptidase inhibitor Drugs 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 229920000249 biocompatible polymer Polymers 0.000 claims 1
- 229920002988 biodegradable polymer Polymers 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000011159 matrix material Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 210000004400 mucous membrane Anatomy 0.000 claims 1
- 238000007911 parenteral administration Methods 0.000 claims 1
- 239000003961 penetration enhancing agent Substances 0.000 claims 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 1
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 abstract 2
- 208000001953 Hypotension Diseases 0.000 abstract 1
- 229940030486 androgens Drugs 0.000 abstract 1
- 230000007423 decrease Effects 0.000 abstract 1
- 230000001648 edemagenic effect Effects 0.000 abstract 1
- 229960001340 histamine Drugs 0.000 abstract 1
- 230000036543 hypotension Effects 0.000 abstract 1
- 230000036470 plasma concentration Effects 0.000 abstract 1
- 230000003578 releasing effect Effects 0.000 abstract 1
- 230000008728 vascular permeability Effects 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/23—Luteinising hormone-releasing hormone [LHRH]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Claims (11)
1. Luteinisierendes Hormon-Releasing Hormon-Antagonist-Peptid,
dessen Struktur SEQ ID No.: 1 ist, worin der AIaninrest in der Sequenzposition 1 N-Acetyl-D-3-(2-naphtyl-)-Ala
ist, der Phenylalaninrest in der Sequenzposition 2 D-3-(4-Chlorphenyl)alanin ist, der Alaninrest in der Sequenzposition
3 D-3(-3-Pyridyl)-Ala ist, der Lysinrest in der Sequenzposition 6 6-Carbamoyllysin ist, der Lysinrest
in der Sequenzposition Nummer 8 N-Isopropyl-Lys ist und der
Alaninrest in der Sequenzposition 10 D-Ala-NH2 ist.
2. Peptid nach Anspruch 1 in Form eines pharmazeutisch verträglichen Salzes.
3. Peptid nach Anspruch 2, worin das pharmazeutisch verträgliche
Salz ein Pamoat- oder Stearatsalz ist.
4. Luteinisierendes Hormon-Releasing Hormon-Antagonist-Peptid,
dessen Struktur durch die Formel SEQ ID No.: 2 wiedergegeben ist, worin der Alaninrest in der Sequenzposition
1 N-Acetyl-D-3-(2-naphthyl)-Ala ist, der Phenylalaninrest in der Sequenzposition 2 D-3-(4-Chlorphenyl)-alanin
ist, der Alaninrest in der Sequenzposition 3 D-3-(3-Pyridyl)-Ala ist, der Lysinrest in der Sequenzposition
6-Carbamoyllysin ist, der Lysinrest in der Sequenzposition Nummer 8 N-Isopropyl-Lys ist und der Prolinrest in der Sequenzposition
9 Pro-NHCH2CH3 ist.
5. Peptid nach Anspruch 4 in Form eines pharmazeutisch verträglichen Salzes.
6. Peptid nach Anspruch 5, worin das pharmazeutisch verträgliche Salz ein Pamoat- oder Stearatsalz ist.
7. Pharmazeutische Präparate, enthaltend als Wirkstoff
ein Peptid nach den Ansprüchen 1 bis 4 im Gemisch mit einem pharmazeutisch verträglichen Träger.
8. Für die parenterale Verabreichung eines Peptids nach den Ansprüchen 1 bis 4 geeignete pharmazeutische Abgabesysteme,
bestehend aus einem biologisch abbaubaren und biologisch verträglichen Polymeren als Matrix.
9. Für die intranasale Abgabe eines Peptids nach den Ansprüchen 1 bis 4 im Gemisch mit einem pharmazeutisch verträglichen
Peptidasehemmer geeignete pharmazeutische Präparate .
10. Für die intranasale Abgabe eines Peptids nach den Ansprüchen 1 bis 4 im Gemisch mit einem pharmazeutisch verträglichen
Penetrationsverstärker für die Schleimhaut geeignete pharmazeutische Präparate.
11. Verwendung der Peptide nach den Ansprüchen 1 bis 4 zur Herstellung eines Medikaments zur wesentlichen Erniedrigung
der Östrogen- und Androgenspiegel im Plasma.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US69086191A | 1991-04-25 | 1991-04-25 | |
| PCT/EP1992/000572 WO1992019651A1 (en) | 1991-04-25 | 1992-03-17 | Luteinizing hormone releasing hormone antagonist peptides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE593491T1 true DE593491T1 (de) | 1994-11-17 |
Family
ID=24774274
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE0593491T Pending DE593491T1 (de) | 1991-04-25 | 1992-03-17 | LHRH-Antagonisten. |
| DE69214818T Expired - Fee Related DE69214818T2 (de) | 1991-04-25 | 1992-03-17 | LHRH-Antagonisten |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE69214818T Expired - Fee Related DE69214818T2 (de) | 1991-04-25 | 1992-03-17 | LHRH-Antagonisten |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US5516887A (de) |
| EP (1) | EP0593491B1 (de) |
| JP (1) | JP2719233B2 (de) |
| AT (1) | ATE144538T1 (de) |
| AU (1) | AU1371892A (de) |
| CA (1) | CA2108977C (de) |
| DE (2) | DE593491T1 (de) |
| DK (1) | DK0593491T3 (de) |
| ES (1) | ES2052488T3 (de) |
| GR (2) | GR940300048T1 (de) |
| HK (1) | HK1006172A1 (de) |
| WO (1) | WO1992019651A1 (de) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6284854B1 (en) * | 1991-07-05 | 2001-09-04 | Biccompatibles Limited | Polymeric surface coatings |
| US6225431B1 (en) * | 1991-07-05 | 2001-05-01 | Biocompatibles Limited | Biocompatibilizing process |
| US5843901A (en) * | 1995-06-07 | 1998-12-01 | Advanced Research & Technology Institute | LHRH antagonist peptides |
| DE19544212A1 (de) * | 1995-11-28 | 1997-06-05 | Asta Medica Ag | Neue LH-RH-Antagonisten mit verbesserter Wirkung |
| US5821230A (en) * | 1997-04-11 | 1998-10-13 | Ferring Bv | GnRH antagonist decapeptides |
| US5925730A (en) * | 1997-04-11 | 1999-07-20 | Ferring Bv | GnRH antagonists |
| WO1999055358A1 (en) * | 1998-04-27 | 1999-11-04 | Praecis Pharmaceuticals Incorporated | Methods for treating hot flashes and gynaecomastia |
| US6235782B1 (en) | 1998-11-12 | 2001-05-22 | Rifat Pamukcu | Method for treating a patient with neoplasia by treatment with a platinum coordination complex |
| US6235776B1 (en) | 1998-11-12 | 2001-05-22 | Cell Pathways, Inc. | Method for treating a patient with neoplasia by treatment with a paclitaxel derivative |
| US6703367B1 (en) * | 1999-04-27 | 2004-03-09 | Praecis Pharmaceuticals Inc. | Methods for treating hot flashes and gynaecomastia |
| DE50114335D1 (de) | 2000-03-14 | 2008-10-30 | Aeterna Zentaris Gmbh | Lh-rh-antagonisten, deren herstellung und verwendung als arzneimittel |
| WO2002002144A1 (en) * | 2000-07-05 | 2002-01-10 | Takeda Chemical Industries, Ltd. | Medicinal preparations for treating sex hormone-dependent diseases |
| GB0117057D0 (en) * | 2001-07-12 | 2001-09-05 | Ferring Bv | Pharmaceutical composition |
| US7098305B2 (en) * | 2001-09-06 | 2006-08-29 | Ardana Bioscience Limited | Sustained release of microcrystalline peptide suspensions |
| EP1778278B1 (de) | 2004-07-16 | 2014-05-21 | Oakwood Laboratories L.L.C. | Gonadotropin-releasing-hormon-antagonisten |
| TWI442932B (zh) | 2008-02-11 | 2014-07-01 | Ferring Int Ct Sa | 以ＧｎＲＨ拮抗劑治療攝護腺癌的方法 |
| WO2010125468A1 (en) * | 2009-05-01 | 2010-11-04 | Ferring International Center Sa | Composition for the treatment of prostate cancer |
| TW201043221A (en) * | 2009-05-06 | 2010-12-16 | Ferring Int Ct Sa | Kit and method for preparation of a Degarelix solution |
| US20110039787A1 (en) * | 2009-07-06 | 2011-02-17 | Ferring International Center S.A. | Compositions, kits and methods for treating benign prostate hyperplasia |
| PT2632934T (pt) | 2010-10-27 | 2017-01-06 | Ferring Bv | Processo para o fabrico de degarelix e seus intermediários |
| EP2447276A1 (de) | 2010-10-27 | 2012-05-02 | Ferring B.V. | Verfahren zur Herstellung von Degarelix und seinen Zwischenprodukten |
| JO3755B1 (ar) | 2011-01-26 | 2021-01-31 | Ferring Bv | تركيبات تستوستيرون |
| AR092840A1 (es) | 2012-06-01 | 2015-05-06 | Ferring Bv | Elaboracion de degarelix |
| US10934244B2 (en) * | 2015-06-15 | 2021-03-02 | Nmd Pharma A/S | Compounds for use in treating neuromuscular disorders |
| US11147788B2 (en) | 2017-12-14 | 2021-10-19 | Nmd Pharma A/S | Compounds for the treatment of neuromuscular disorders |
| US11730714B2 (en) | 2017-12-14 | 2023-08-22 | Nmd Pharma A/S | Compounds for the treatment of neuromuscular disorders |
| CN113527438A (zh) * | 2021-08-30 | 2021-10-22 | 湖南三太药业有限公司 | 一种全液相合成丙氨瑞林的方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4740500A (en) * | 1985-01-31 | 1988-04-26 | The Salk Institute For Biological Studies | GnRH antagonists VIII |
| US5003011A (en) * | 1985-04-09 | 1991-03-26 | The Administrators Of The Tulane Educational Fund | Therapeutic decapeptides |
| US4801577A (en) * | 1987-02-05 | 1989-01-31 | Syntex (U.S.A.) Inc. | Nonapeptide and decapeptide analogs of LHRH useful as LHRH antagonists |
| US4851385A (en) * | 1987-07-15 | 1989-07-25 | Indiana University Foundation | LHRH antagonist analogs having low histamine-release activity |
| US4800191A (en) * | 1987-07-17 | 1989-01-24 | Schally Andrew Victor | LHRH antagonists |
| US4935491A (en) * | 1987-08-24 | 1990-06-19 | Board Of Regents, The University Of Texas System | Effective antagonists of the luteinizing hormone releasing hormone which release negligible histamine |
| US5110904A (en) * | 1989-08-07 | 1992-05-05 | Abbott Laboratories | Lhrh analogs |
-
1992
- 1992-03-17 AU AU13718/92A patent/AU1371892A/en not_active Abandoned
- 1992-03-17 AT AT92906562T patent/ATE144538T1/de not_active IP Right Cessation
- 1992-03-17 ES ES92906562T patent/ES2052488T3/es not_active Expired - Lifetime
- 1992-03-17 DK DK92906562.1T patent/DK0593491T3/da active
- 1992-03-17 CA CA002108977A patent/CA2108977C/en not_active Expired - Fee Related
- 1992-03-17 WO PCT/EP1992/000572 patent/WO1992019651A1/en active IP Right Grant
- 1992-03-17 US US08/140,045 patent/US5516887A/en not_active Expired - Lifetime
- 1992-03-17 DE DE0593491T patent/DE593491T1/de active Pending
- 1992-03-17 DE DE69214818T patent/DE69214818T2/de not_active Expired - Fee Related
- 1992-03-17 EP EP92906562A patent/EP0593491B1/de not_active Expired - Lifetime
- 1992-03-17 JP JP4505977A patent/JP2719233B2/ja not_active Expired - Fee Related
-
1994
- 1994-07-29 GR GR940300048T patent/GR940300048T1/el unknown
-
1996
- 1996-12-23 GR GR960403590T patent/GR3022144T3/el unknown
-
1998
- 1998-06-15 HK HK98105279A patent/HK1006172A1/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| WO1992019651A1 (en) | 1992-11-12 |
| ES2052488T1 (es) | 1994-07-16 |
| JP2719233B2 (ja) | 1998-02-25 |
| DE69214818D1 (de) | 1996-11-28 |
| JPH06507604A (ja) | 1994-09-01 |
| EP0593491B1 (de) | 1996-10-23 |
| ES2052488T3 (es) | 1997-01-01 |
| GR3022144T3 (en) | 1997-03-31 |
| ATE144538T1 (de) | 1996-11-15 |
| AU1371892A (en) | 1992-12-21 |
| CA2108977A1 (en) | 1992-10-26 |
| EP0593491A1 (de) | 1994-04-27 |
| GR940300048T1 (en) | 1994-07-29 |
| HK1006172A1 (en) | 1999-02-12 |
| DK0593491T3 (da) | 1997-03-17 |
| US5516887A (en) | 1996-05-14 |
| DE69214818T2 (de) | 1997-02-27 |
| CA2108977C (en) | 2002-12-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE593491T1 (de) | LHRH-Antagonisten. | |
| US5137872A (en) | Growth hormone-releasing factor analogs | |
| FI94353C (fi) | Menetelmä terapeuttisesti käyttökelpoisen bradykiniiniantagonistin valmistamiseksi | |
| US6242563B1 (en) | Peptide analogues | |
| EP0559756B1 (de) | Nonapeptide als bombesinantagonisten | |
| PT736039E (pt) | Compostos com propriedades para liberar a hormona de crescimento | |
| EP2161282A1 (de) | PACAP-Peptidanaloge | |
| JP3838656B2 (ja) | ポリペプチドのボンベシン拮抗物質 | |
| CA2023194C (en) | Peptides having bradykinin antagonist action | |
| WO1994021674A9 (en) | Polypeptide bombesin antagonists | |
| US4801456A (en) | Growth hormone-releasing factor analogs | |
| WO1995004540A1 (en) | N-terminus modified analogs of lhrh | |
| USRE33699E (en) | Growth hormone-releasing factor analogs | |
| TW200530270A (en) | Pharmaceutical composition for treating tumors comprising growth hormone releasing compounds or their antagonists | |
| EP0328090A2 (de) | LHRH-Analoge | |
| EP0683792B1 (de) | Lhrh antagonisten mit modifizierten aminoacylresten an den positionen 5 und 6 | |
| ES2017028A6 (es) | Procedimiento para preparar antagonistas de bombesina. | |
| US5648333A (en) | Peptides having bradykinin antagonist action | |
| EP0328089A2 (de) | LHRH-Analoge reduzierter Grösse | |
| O Moustafa et al. | The Importance of Amino Acid and Peptide Chemistry in the Treatment of the Major Diseases: Neuropeptides | |
| WO1995024424A1 (en) | Cyclic peptide lhrh antagonists | |
| EP0346068A3 (de) | D-Cys6-Vasopressin-Antagonisten | |
| HRP921277A2 (en) | Nonapeptide bombestin antagonists | |
| EP0364819A2 (de) | LHRH-Analoge | |
| KONIG | STRUCTURE-ACTIVITY RELATIONSHIPS IN THE LH-RH |